Program
dostarlimab
Also written as “Dostarlimab”, “TSR-042” and “Dostarlimab (TSR-042)”.
Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 2517 open or running | phase 4since Mar 20, 2025 | Mar 9, 2016 | Nov 23, 2026phase 2 · NCT06567782 |
| AGO Research | 10 open or running | phase 2since Oct 18, 2021 | Oct 18, 2021 | none ahead |
Also a collaborator on its studies: iteos-therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Mar 9, 2016.
- Feb 2, 20232 phase 2 studiesGlaxoSmithKline · NCT05723562, NCT05751629
- May 3, 2023Phase 3 study in Colonic NeoplasmsGlaxoSmithKline · NCT05855200 · 892 planned · United States, Argentina, Australia and more
- Feb 5, 2024Phase 3 study in Head and Neck NeoplasmsGlaxoSmithKline · NCT06256588 · 864 planned · United States, Argentina, Australia and more
- Mar 12, 2024Phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311 · 41 enrolled · Japan
- Jun 18, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT06472076 · 88 enrolled · United States, Argentina, Belgium and more
- Aug 20, 2024Phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782 · 120 planned · Belgium, Italy, Japan and more
- Oct 10, 20242 phase 2 studiesGlaxoSmithKline · NCT06640049, NCT06655818
- Mar 20, 2025Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT06897527 · 100 planned
- Aug 5, 2025Phase 2 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07108270 · 30 planned · China
- Jun 11, 2026Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07652515 · 100 planned
- Jul 24, 2026Phase 3 study in Rectal NeoplasmsGlaxoSmithKline · NCT07740720 · 100 planned · Japan
- Sep 30, 2026Phase 3 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07860450 · 378 planned
- Nov 2, 2026Primary completion moved from 2026-07-15 to 2026-12-14Date moved laterphase 2 · +5 months · NCT06317311
- Nov 16, 2026Primary completion moved from 2029-12-12 to 2030-03-13Date moved laterphase 3 · +3 months · NCT07740720
Ahead
- Nov 2, 2026Primary completion: phase 2 study in Rectal NeoplasmsGlaxoSmithKline · NCT05723562
- Nov 23, 2026Primary completion: phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782
- Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
- Dec 14, 2026Primary completion: phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07860450Endometrial Neoplasms | 3 | Not yet recruiting | GlaxoSmithKline | Nov 5, 2030 | 378 |
| NCT07740720Rectal Neoplasms · Japan | 3 | Not yet recruiting | GlaxoSmithKline | Mar 13, 2030 | 100 |
| NCT07652515Endometrial Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Aug 30, 2030 | 100 |
| NCT07108270Endometrial Neoplasms · China | 2 | Recruiting | GlaxoSmithKline | Mar 31, 2030 | 30 |
| NCT06897527Endometrial Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Jan 13, 2027 | 100 |
| NCT06655818Multiple Myeloma · France, Korea, Republic of | 2 | Terminated | GlaxoSmithKline | Feb 14, 2024 | 4 |
| NCT06640049Rectal Neoplasms · China | 2 | Active, not recruiting | GlaxoSmithKline | Oct 24, 2027 | 23 |
| NCT06567782Colonic Neoplasms · Belgium, Italy, Japan and more | 2 | Recruiting | GlaxoSmithKline | Nov 23, 2026 | 120 |
| NCT06472076Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 30, 2026 | 88 |
| NCT06317311Carcinoma · Japan | 2 | Active, not recruiting | GlaxoSmithKline | Dec 14, 2026 | 41 |
| NCT06256588Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Jun 30, 2028 | 864 |
| NCT05855200Colonic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Mar 19, 2029 | 892 |
| NCT05751629Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Apr 1, 2022 | 41 |
| NCT05723562Rectal Neoplasms · United States, Canada, France and more | 2 | Active, not recruiting | GlaxoSmithKline | Nov 2, 2026 | 154 |
| NCT05126342Ovarian Neoplasms | 2 | Withdrawn | AGO Research | Nov 1, 2024 | 0 |
| NCT04655976Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 5, 2025 | 758 |
| NCT04544995Neoplasms · United Kingdom | 1 | Terminated | GlaxoSmithKline | Apr 23, 2025 | 47 |
| NCT04581824Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Terminated | GlaxoSmithKline | Aug 4, 2022 | 243 |
| NCT04126200Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 208 |
| NCT03981796Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Nov 26, 2026 | 785 |
| NCT03955471Ovarian Neoplasms · United States | 2 | Terminated | GlaxoSmithKline | Aug 18, 2021 | 41 |
| NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Oct 31, 2024 | 1,400 |
| NCT03574779Ovarian Neoplasms · United States, Canada, Spain | 2 | Completed | GlaxoSmithKline | Jun 28, 2024 | 77 |
| NCT03308942Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 4, 2020 | 53 |
| NCT03307785Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Feb 26, 2020 | 60 |
| NCT02715284Neoplasms · United States, Argentina, Brazil and more | 1 | Active, not recruiting | GlaxoSmithKline | May 18, 2026 | 729 |
How it is read
Names in the registry
- “Dostarlimab”, 22 entries
- “TSR-042”, 2 entries
- “Dostarlimab (TSR-042)”, 1 entry
- “TSR-042 (Dostarlimab)”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 5 studies
- Endometrial Neoplasms, 4 studies
- Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Rectal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.